News Bayer CEO confident firm can cope with Xarelto hit Bayer's CEO says new product launches will offset the decline in sales of anticoagulant Xarelto over the course of 2025.
News BridgeBio gets EU nod for ATTR cardiomyopathy drug BridgeBio and Bayer are poised to challenge Pfizer's Vyndaqel in the EU after acoramidis gets a green light for ATTR cardiomyopathy.
News ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
